Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06345495 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06345495 · ClinicalTrials.gov record · last posted 2026-08-20

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

StatusRecruiting
PhasePhase 2
Started2024-10-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

Amendment record 10 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 10 times since 2024-04-02; most recent amendment 2026-03-09. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-10-07
Status change Not Yet Recruiting→Recruitingv4
Trial Details
NCT Number NCT06345495
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Incyte Corporation
Conditions Splenomegaly, Myelofibrosis
Enrollment 30 participants
Start Date 2024-10-01
Primary Completion 2027-01-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-20